The reduction in price target by Cantor Fitzgerald, despite maintaining an Overweight rating, suggests that the analyst sees less upside potential for Prothena Corp's stock in the short term. This could lead to a negative investor sentiment and a potential decrease in the stock price as the market adjusts to the new target.